Immunotherapy in Ovarian Cancer

1. Immunological Basis

• Regulatory T cells (Tregs) that secrete IL-10 and TGF-beta, dampening cytotoxic responses
• Tumor-derived IL-6 that promotes tumor cell growth and modulates immune function
• Myeloid-derived suppressor cells (MDSCs) and immunosuppressive IDO (indoleamine 2,3-dioxygenase) production
• T-cell exhaustion driven by chronic tumor antigen exposure, which upregulates checkpoint receptors (PD-1, CTLA-4, TIM-3, LAG-3)
• Low mutational burden: High-grade serous ovarian cancer (HGSOC) has relatively few somatic mutations, meaning fewer neoantigens for T cells to recognize - a key reason why single-agent checkpoint inhibitors have been less effective than in MSI-high or TMB-high tumors

2. Types of Immunotherapy Approaches

A. Immune Checkpoint Inhibitors (ICIs)

• Anti-PD-1: Nivolumab, pembrolizumab
• Anti-PD-L1: Atezolizumab, avelumab, durvalumab
• Anti-CTLA-4: Ipilimumab
• Combination CTLA-4 + PD-1 blockade: Different, non-redundant mechanisms; combination induces ~50% tumor regression in melanoma and is being explored in ovarian cancer

B. Cytokine Therapy

C. Cancer Vaccines

• Personalized neoantigen vaccines: Early data show these can effectively mobilize antitumor T-cell immunity in ovarian cancer (Science Translational Medicine, 2018)
• CA-125 targeting vaccines: Investigated in trials but limited clinical success as monotherapy
• Dendritic cell vaccines: Phase I/II explored; synergy with checkpoint blockade is under study

D. Adoptive Cell Therapy (ACT)

• TIL therapy: Tumor-infiltrating lymphocytes expanded ex vivo and reinfused; phase I/II studies ongoing in ovarian cancer
• CAR-T cells: Targeting antigens such as folate receptor alpha (FRalpha), mesothelin, and MUC16 (CA-125); early trials underway with challenges around solid tumor penetration
• CAR-NK cells: Emerging data (2025) with CRISPR-based enhancement of NK cell potency

E. Antibody-Dependent Cellular Cytotoxicity (ADCC)

3. Major Clinical Trials and Results

First-Line Setting

Recurrent Setting

• ICI monotherapy has shown limited activity
• The SOLACE2 phase II trial (2025) tested olaparib + durvalumab + cyclophosphamide in platinum-sensitive disease

• The ARTISTRY-7 phase III trial (nemvaleukin alfa + pembrolizumab) was terminated early in March 2025 for lack of survival benefit
• FDA Approval (2025): Pembrolizumab + paclitaxel (with or without bevacizumab) was approved for platinum-resistant ovarian cancer - the first FDA approval of a checkpoint inhibitor specifically for ovarian cancer

4. The Meta-Analytic Picture (2025-2026)

• Overall, anti-PD-1/PD-L1 did not significantly improve PFS vs. control (HR 0.98; 95% CI 0.85-1.12; I² = 67%)
• No significant benefit in first-line (HR 0.93) or recurrent settings (HR 1.07)
• Non-significant trend favoring ICI + PARP inhibitor in HR-proficient patients (HR 0.77; 95% CI 0.65-0.92)

• PD-1/PD-L1 + chemotherapy and PD-1/PD-L1 + ipilimumab showed the greatest PFS/OS benefit
• ICI + chemo improved ORR most markedly (OR 3.06; 95% CI 1.42-6.60)
• PD-L1 expression is a potential predictive biomarker - PD-L1-positive patients showed better outcomes with ICI + chemotherapy

• 7 phase III trials (5,671 patients)
• Single-agent PD-L1 inhibitor trials: no significant efficacy in newly diagnosed EOC
• Triplet durvalumab + bevacizumab + olaparib: longer PFS than bevacizumab alone in non-BRCA-mutated patients
• ICI ineffective in platinum-sensitive and platinum-resistant recurrent EOC as monotherapy

5. Why Has Immunotherapy Underperformed vs. Other Cancers?

1. Low tumor mutational burden (TMB): HGSOC has fewer neoantigens than melanoma or NSCLC
2. Immunosuppressive TME: Ascites contains abundant Tregs, IL-10, TGF-beta, MDSCs
3. Low MSI/dMMR prevalence: Only ~5% of ovarian cancers are MSI-high (those benefit most from checkpoint inhibition)
4. PD-L1 is inconsistently expressed and is not a reliable single biomarker in ovarian cancer
5. T-cell exhaustion and metabolic reprogramming within the TME limit ICI reversal of exhaustion

6. Predictive Biomarkers (Emerging)

7. Emerging Strategies and Future Directions

• CTLA-4 + PD-1 dual blockade: Under investigation; dual blockade may overcome the immunosuppressive TME more effectively than single-agent
• ICI + PARP inhibitor combinations: Most promising signal to date (DUO-O); synergy proposed through PARP-trapping increasing genomic instability and immunogenicity
• ICI + anti-angiogenics (bevacizumab): Bevacizumab may "normalize" the tumor vasculature to improve T-cell infiltration
• Bispecific antibodies: Targeting TAAs (e.g., FRalpha, mesothelin) while engaging T cells
• mRNA/neoantigen vaccines + ICI: Personalized vaccine priming followed by checkpoint blockade
• IL-4 blockade: Preclinical data suggest IL-4 drives immunosuppression in ascites; dupilumab (anti-IL-4Ra) being explored to sensitize tumors to ICI
• IPROC platform trial (Canada, 2026): Ongoing multi-arm platform study specifically for platinum-resistant HGSOC, now enrolling clear cell ovarian cancer

Summary

1. Pembrolizumab + paclitaxel ± bevacizumab: FDA-approved for platinum-resistant ovarian cancer (2025)
2. Durvalumab + bevacizumab + olaparib: Most promising first-line triplet in non-BRCA-mutated HRD+ disease (DUO-O, 2026 publication), though OS data are immature
3. Monotherapy ICI: Generally ineffective in unselected ovarian cancer populations
4. Future focus: Biomarker-selected populations, combination strategies with PARP inhibitors and anti-angiogenics, and novel modalities (CAR-T, vaccines, bispecifics)

Recent evidence note: The 2026 meta-analysis (Vida et al., PMID 41763143) confirms no overall PFS benefit from anti-PD-1/PD-L1 in advanced ovarian cancer across 10 RCTs, while Ahmadi et al. 2025 (PMID 40650991) suggests combinations with chemotherapy or ipilimumab may offer benefit particularly in PD-L1-positive patients. This is a rapidly evolving field - ongoing trials will likely refine which patients benefit.